Phase 2 Study of Autologous Tumor Lysate-pulsed DC-CIK Cell in Colorectal Cancer After Surgery

Trial Profile

Phase 2 Study of Autologous Tumor Lysate-pulsed DC-CIK Cell in Colorectal Cancer After Surgery

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2015

At a glance

  • Drugs Dendritic cell activated cytokine-induced killer cells-Shenzhen Hornetcorn (Primary) ; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Shenzhen Hornetcorn Biotechnology
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Jun 2015 Planned End Date changed from 1 Oct 2017 to 1 Dec 2017 as reported by ClinicalTrials.gov.
    • 05 Jun 2015 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top